Subjective perception versus objective outcome after intravitreal ranibizumab for exudative AMD

Area of Science:

• Ophthalmology
• Retinal Diseases
• Pharmacological Treatments

Background:

• Ranibizumab is effective in preserving visual acuity in exudative age-related macular degeneration (AMD).
• Statistical significance in outcome measures like best-corrected visual acuity (BCVA) may not always reflect clinical relevance for patients.
• Patient-perceived treatment success is crucial for determining clinical relevance.

Purpose of the Study:

• To investigate the relationship between patients' subjective perception of treatment success and objective outcomes after intravitreal ranibizumab for exudative AMD.
• To identify objective visual acuity thresholds that correspond to a patient's perception of meaningful improvement.

Main Methods:

• Prospective interventional case series involving three monthly ranibizumab injections for exudative AMD.
• Subjective Study Outcome (SSO) assessed by patient grading of visual quality 4 weeks post-injection.
• Objective assessment included BCVA, reading visual acuity (RVA), reading speed, and central retinal thickness (OCT).

Main Results:

• Mean BCVA increased by +3.16 ETDRS letters (p=0.03).
• 68% of patients reported a subjective improvement (SSO), 21% reported no change, and 11% reported worsening.
• SSO significantly correlated with changes in BCVA, RVA, and reading speed, but not with central retinal thickness.
• A gain of ≥+5 ETDRS letters correlated with significantly better SSO, with >80% subjective improvement seen at ≥+7 letters.

Conclusions:

• Two-thirds of patients experienced subjective visual improvement following ranibizumab treatment.
• Patient perception of improvement is significantly linked to objective changes in BCVA and RVA.
• A gain of +5 to +7 ETDRS letters appears to be a clinically meaningful threshold for perceived improvement in exudative AMD patients.